Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells

International Journal of Cancer

Volumn 68, Issue 3, 1996, Pages 340-348

  De Vincenzo, Rosa ^a   Scambia, Giovanni ^a   Panici, Pierluigi Benedetti ^a   Fattorossi, Andrea ^a   Bonanno, Giuseppina ^a   Ferlini, Cristiano ^a   Isola, Giulio ^a   Pernisco, Stefania ^a   Mancuso, Salvatore ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DOXORUBICIN; FULVESTRANT; GLYCOPROTEIN P; TAMOXIFEN;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; DNA, NEOPLASM; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ESTRADIOL; ESTROGEN ANTAGONISTS; FLOW CYTOMETRY; HUMANS; P-GLYCOPROTEIN; PHENOTYPE; PLOIDIES; RECEPTORS, ESTROGEN; RHODAMINE 123; RHODAMINES; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0029852016     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19961104)68:3<340::AID-IJC12>3.0.CO;2-C     Document Type: Article

References (26)

1. ANTONELLI, G., TURRIZIANI, O., CIANFRIGLIA, M., RIVA, E., DONG, G., FATTOROSSI, A. and DIANZANI, F., Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug-resistance P-glycoprotein. AIDS Res. hum. Retrov., 8, 1839-1844 (1992).
2. BERENBAUM, K.C., Criteria for analyzing interaction between biologically active agents. Advanc. Cancer Res., 25, 269-335 (1981).
3. BERMAN, E., ADAMS, M., DUIGOU-OSTERNDORF, R., GODFREY, L., CLARKSON, B. and ANDREEFF, M., Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood, 77, 818-825 (1991).
4. CALLAGHAN, R. and HIGGINS, C.F., Interaction of tamoxifen with the multidrug-resistance P-glycoprotein.Brit. J. Cancer, 71, 294-299 (1995).
5. CHATTERJEE, M. and HARRIS, A.L., Reversal of drug resistance to adriamycin in CHO cells by tamoxifen and 4-hydroxytamoxifen: role of drug interaction with alfa 1 acid glycoprotein. Brit. J. Cancer, 62, 712-717 (1990).
6. CORADINI, D., BIFFI, A., CAPPELLETTI, V. and DI FRONZO, G., Activity of tamoxifen and new anti-estrogens on estrogen-receptor-positive and -negative breast-cancer cells. Anticancer Res., 14, 1059-1064 (1994).
7. DEFRIEND, D.J., HOWELL, A., NICHOLSON, R.I., ANDERSON, E., DOWSETT, M., MANSEL, R.E., BLAMEY, R.W., BUNDRED, N.J., ROBERTSON, J.F., SAUNDERS, C., BAUM, M., WALTON, P., SUTCLIFFE, F. and WAKELING, A.E., Investigation of a new pure anti-estrogen (ICI 182,780) in women with primary breast cancer. Cancer Res., 54, 408-414 (1994).
8. DEGREGORIO, M.W., FORD, J.M., BENZ, C.C. and WIEBE, V.J., Toremifene: pharmacological and pharmacokinetic basis of reversing multidrug resistance. J. clin. Oncol., 7, 1359-1364 (1989).
9. FOSTER, B.J., GROTZING, K.R., MCKOY, W.M., RUBISTEIN, L.W. and HAMILTON, T.C., Modulation of induced resistance to adriamycin in two breast-cancer cell lines with tamoxifen or perhexiline maleate. Cancer Chemother. Pharmacol., 22, 147-152 (1988).
10. KANG, Y. and PERRY, R.R., Modulatory effects of tamoxifen and recombinant human α-interferon on doxorubicin resistance. Cancer Res., 53, 3040-3045 (1993).
11. KIRK, J., HOULBROOK, S., STUART, N.S.A., STRATFORD, I.J., HARRIS, A.L. and CARMICHAEL, J., Differential modulation of doxorubicin to multidrug and intrinsically drug-resistant cell lines by anti-oestrogens and their major metabolites. Brit. J. Cancer, 67, 1189-1195 (1993).
12. KIRK, J., SYED, S.K., HARRIS, A.L., IARMAN, M., ROUFOGALIS, B.D., STRATFORD, I.J. and CARMICHAEL, J., Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-estrogen and novel tamoxifen derivates. Biochem. Pharmacol., 48, 277-285 (1994).
13. KISS, Z. and CRILLY, K.S., Tamoxifen inhibits uptake and metabolism of ethanolamine and choline in multidrug-resistant, but not in drug-sensitive, MCF-7 human breast-carcinoma cells. FEBS Lett., 360, 165-168 (1995).
14. r 170,000 glycoprotein (gp170)-binding studies. Cancer Res., 54, 441-447 (1994).
15. MOSCOW, J.A., SCHNEIDER, E. and COWAN, K.H., Multidrug resis tance. Cancer Chemother. biol. Response Modifiers Annual, 15, 99-129 (1994).
16. NEYFAKH, A.A., Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp. Cell. Res., 174, 168-176 (1988).
17. RADERER, M. and SCHEITHAUER, W., Clinical trials of agents that reverse multidrug resistance. Cancer, 72, 3553-3563 (1993).
18. RAO, U.S., FINE, R.L. and SCARBOROUGH, G.A., Anti-estrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem. Pharmacol., 48, 287-292 (1994).
19. SALMON, S.E., DALTON, W.S., GROGAN, T.M., PLEZIA, P., LEHNERT, M., ROE, D.J. and MILLER, P., Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as chemosensitizer. Blood, 78, 44-50 (1991).
20. SCAMBIA, G., RANELLETTI, P.O., BENEDETTI PANICI, P., DE VINCENZO, R., BONANNO, G., FERRANDINA, G., PIANTELLI, M., BUSSA, S., RUMI, C., CIANFRIGLIA, M. and MANCUSO, S., Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol., 34, 459-464 (1994).
21. TRUMP, D.L., SMITH, D.C., ELLIS, P.C., ROGERS, M.P., SCHOLD, C.S., WINER, E.P., PANELLA, T.J., JORDAN, V.C. and FINE, R.L., High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase-I trial in combination with vinblastine. J. nat. Cancer Inst., 84, 1811-1816 (1992).
22. WADLER, S., GREEN, M.D., BASCH, R. and MUGGIA, P.M., Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine,(+)-1,2,-bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF 187) on murine sarcoma S180 in vitro. Biochem. Pharmacol., 9, 1495-1501 (1987).
23. WAKELING, A.E., The future of new pure anti-estrogens in clinical breast cancer. Breast Cancer Res. Treat., 25, 1-9 (1993).
24. WILSON, J.W., WAKELING, A.E., MORRIS, I.D., HICKMAN, J.A. and DIVE, C., MCF-7 human mammary-adenocarcinoma cell death in vitro in response to hormone withdrawal and DNA damage. Int. J. Cancer, 61, 502-508 (1995).
25. WISEMAN, H., Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. TiPS, 15, 83-89 (1994).
26. ZALCBERG, J.R., HU, X.F., CHING, M., WAKELING, A., WALL, D.M., MARSCHNER, I.C. and DE LUISE, M., Differential effects of estrogen, tamoxifen and the pure anti-estrogen ICI 182,780 in human drug-resistant leukaemia cell lines. Cancer Chemother. Pharmacol., 33, 123-129 (1993).